Maravai Lifesciences Holdings (MRVI) Receivables (2020 - 2026)

Maravai Lifesciences Holdings' Receivables history runs 7 years deep, the most recent figure standing at $33.4 million for Q1 2026.

• On a quarterly basis, Receivables rose 17.27% year-over-year to $33.4 million in Q1 2026; TTM through Mar 2026 was $33.4 million, a 17.27% increase from a year earlier, with the FY2025 full-year figure at $25.5 million, down 35.04% from the prior year.
• Receivables advanced to $33.4 million in Q1 2026 per MRVI's latest filing, from $25.5 million in the prior quarter.
• Across five years, Receivables topped out at $120.4 million in Q1 2022 and bottomed at -$2.4 million in Q4 2023.
• The 5-year median for Receivables is $36.3 million (2024), against an average of $48.9 million.
• Across the five-year window, Receivables tumbled 59.96% in 2023 and soared 1670.29% in 2024, its largest moves.
• Year by year, Receivables stood at $114.1 million in 2022, then tumbled by 102.11% to -$2.4 million in 2023, then surged by 1670.29% to $37.8 million in 2024, then tumbled by 32.62% to $25.5 million in 2025, then soared by 31.05% to $33.4 million in 2026.
• Per Business Quant, the three latest MRVI Receivables figures stand at $33.4 million (Q1 2026), $25.5 million (Q4 2025), and $22.5 million (Q3 2025).